Loading…

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Wednesday, March 7
 

9:00am GMT

Mosaic User Group Meeting organised by Titian
If you are a Mosaic User, Titian will be hosting its Mosaic User Group Meeting in Berlin ahead of the conference. 

Wednesday March 7, 2018 9:00am - 6:00pm GMT
NH Berlin AlexanderPlatz Landsberger Allee 26 10249 Berlin - Germany
 
Thursday, March 8
 

9:00am GMT

Welcome Coffee and Registration
Thursday March 8, 2018 9:00am - 9:45am GMT
Music Hall 1-2-3

9:45am GMT

Welcome
Speakers
avatar for Clive Green

Clive Green

Executive Director, AstraZeneca
Clive received undergraduate and postgraduate degrees in Chemistry from the University of Nottingham, UK. He then completed postdoctoral research at the University of Pennsylvania, USA, before returning to the UK in 2001 as a medicinal chemistry Team Leader with AstraZeneca. As a... Read More →


Thursday March 8, 2018 9:45am - 10:00am GMT
Music Hall 4

10:00am GMT

Session 1 - Our Way: The Process of Compound Management
Our Way: the Process of Compound Management  - session designed to learn from peers how they manage CM processes

Computational Chemistry and Machine Learning approaches to building the Idorsia Screening Compound Collection - Julien Hazemann
In 2013 Actelion had decided to establish a Compound Library Committee (CLC), a cross-functional team consisting of computational scientists, medicinal chemists and a biologist. The CLC was endowed with a significant annual budget for new screening compound purchases. Based on an initial library analysis performed in 2013, the CLC developed a New Library Strategy. The structural library quality was increased and this was achieved by shifting the selection criteria from ‘druglike’ to ‘leadlike’ structures, enriching for non-flat structures, aiming for compound novelty, and increasing the ratio of higher cost ‘Premium Compounds’. Novel chemical space was gained by adding natural compounds, macrocycles, designed and focused libraries to the collection, and through mutual exchanges of proprietary compounds with agrochemical companies. To support anti-infective programs with their distinct requirements, a library of compounds having the potential to be retained by Gram-negative bacteria was built. To this end, a Machine Learning technique was applied to a large experimental data set that was specifically generated for the purpose. A comparative analysis in 2016 provided evidence for the positive impact of all these measures on new lead discovery. Screening the improved library has provided several highly promising hits, including a macrocyclic compound, that are currently followed up in different Hit-to-Lead and Lead Optimization programs. The goal of the CLC was not to achieve higher HTS hit rates, but to increase the chances of identified hits to serve as the basis of successful early drug discovery programs. The experience gathered so far legitimates the New Idorsia Library Strategy.

Remodeling compound management:  Implementing new technology while maintaining business continuity - Marybeth Burton
Automated compound storage and distribution accompanied by robotic liquid handling has become an industry standard for managing corporate compound collections.   In the early 2000s many ‘early adopter’ pharmaceutical companies invested heavily in automation and facilities built to distribute and preserve their compound collections.  Obsolescence has become a major issue with these aging systems leading these same pharma companies to upgrade existing systems, invest in new equipment and/or facilities, or utilize CRO resources to manage their collections.  This case study will highlight business continuity, logistics, and informatics challenges encountered and addressed by the MSD Discovery Sample Management group during a major capital project to upgrade compound management infrastructure.

Compound handling in the externalised research environment - David Cronk
Recent years has seen an increase in the role played by external research providers in the discovery and development of new pharmaceuticals and agrochemicals, across a broad spectrum of capabilities.  In order to support the areas of high throughput screening, compound profiling, hit-to-lead and lead optimisation activities Charles River, like most contract research organisations, has evolved its compound management facility to keep pace with increasing demand for biology and chemistry services.  In keeping with large pharma and for reasons of efficiency, compound management is a centralised activity and is the hub for compound receipt, provision of compound plates for screening, profiling and other assay activities such as ADME profiling.
 During the presentation we will describe the processes in place which mirror those accepted as industry best practice but with flexibility to meet the varying requirements of individual customer needs.  An overview of the infrastructure that has been established to handle the receipt and dispatch of solid and liquids from and to multiple collaborators, each with their own standard, will also be provided, including how the software systems are implemented to ensure the integrity of customer sensitive data.

An Insight into Compound Management in an Academic Setting - Kisty Cookson
The Drug Discovery Unit at the University of Dundee is a fully operational, integrated drug discovery group working across multiple disease areas. We collaborate with partners to translate world-class biology research into validated drug targets and candidate drugs to address unmet medical need across our two areas of activity; Diseases of the Developing World and Innovative Targets Portfolio. The Drug Discovery Unit has undergone a number of expansions since its inception and the need for a dedicated Compound Management team soon became apparent. The team was created 6 years ago with a single person using a Biomek FXP and a Labcyte Echo. Within the year the team had expanded to three people and a second Echo. This marked the beginning of the team establishing itself as a true benefit as an in-house team and the efficiencies it brought.

Outsourcing for the Research Environment - Christof Sturm 
Novartis Pharma AG recently made a strategic decision to increase the externalization of scientific activities in the Drug Metabolism and Pharmacokinetics (DMPK) department. Up to 80% of the volume of standard DMPK discovery assays are now externalized, which represents an increase of approximatively 100`000 samples/year in a global environment. Therefore a different outsourcing model was chosen which included a centralized workflow tracking system and a newly founded group with a central role for high volume, routine, Research assays. The group’s main tasks were to establish and manage external service provider workflows including samples and data logistics. I will present a brief overview on how we approached this challenge in terms of setup, logistics, turn-around times, what hurdles we had to face and where we are standing now.

Speakers
avatar for Marybeth Burton

Marybeth Burton

Executive Director Disc Sa, Merck and Co.
Marybeth Burton leads Merck’s Discovery Sample Management group based at the Rahway, New Jersey site. She is responsible for both small molecule compound and chemical inventory management activities. Her group monitors compound collection quality and participates in efforts to continuously... Read More →
avatar for Kirsty Cookson

Kirsty Cookson

Mrs, University of Dundee
Kirsty received her undergraduate degree in Drug Design and Mechanisms from the University of Dundee in 2011. She then went on to do a Masters of Research in Cancer Biology also at the University of Dundee which she completed in 2012. She started working for the University of Dundee... Read More →
avatar for David Cronk

David Cronk

Director, HTS Sciences, Charles River
David has been with Charles River Laboratories, since 2005 and has responsibility for HTS and the associated assay development and compound management activities.  In this role he discusses hit finding projects with potential and existing clients across the pharmaceutical sector... Read More →
avatar for Julien Hazemann

Julien Hazemann

Computational Chemistry Specialist, Idorsia
Julien joined the Drug Discovery Chemistry Department of Actelion Pharmaceuticals in 2007. From 2013, he was in charge of designing and maintaining the corporate screening collection and provides strategic partnership and operational support to the Hit-to-Lead and Drug Discovery projects.Upon... Read More →
avatar for Christof Sturm

Christof Sturm

Senior Specialist, Outsourcing Logistics, Novartis Pharma AG
Senior Specialist for Outsourcing Logistics at Novartis Pharma AG in Basel, SwitzerlandIn his current role, he supports the establishment of an efficient, cost-effective and flexible infrastructure which enables the outsourcing of routine scientific activities across Research.Christof... Read More →


Thursday March 8, 2018 10:00am - 12:05pm GMT
Music Hall 4

12:05pm GMT

Vendor Snapshot Presentations - Titian & Wagner
David Booth - Titian
Scott VanderWoude -Wagner

Thursday March 8, 2018 12:05pm - 12:15pm GMT
Music Hall 4

12:15pm GMT

Networking Lunch and Exhibition
Thursday March 8, 2018 12:15pm - 1:15pm GMT
Music Hall 1-2-3

1:15pm GMT

Keynote Speaker: Anton Simeonov - Increasing Efficiency in Early Discovery through Improved Sample Management and Data Analysis Processes
Increasing Efficiency in Early Discovery through Improved Sample Management and Data Analysis Processes
The mission of the National Center for Advancing Translational Sciences (NCATS) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of interventions across a wide range of human diseases and conditions. There are several thousand known diseases affecting humankind and treatments are available for only several hundred of them, with new drugs taking more than a decade and costing over one billion dollars to develop. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying therapeutic solutions. An introduction of the Center’s intramural operations will be presented, focusing on the use of advanced assay and chemistry technologies to address the wide range of needs associated with early discovery space. Examples will be provided of novel approaches and improvements in the areas of disease model-building through 3D tissue bioprinting technology development, compound processing for high-throughput discovery of synergistic drug-drug combinations, and high-efficiency protocols utilizing induced pluripotent stem cells. Further, highlights of the center’s efforts to introduce environmentally-friendly approaches to sample management (i.e., to make screening green again) will be presented.

Anton Simeonov is the scientific director of the intramural Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH). The author or inventor on more than 145 peer-reviewed scientific publications and patents, Simeonov has a truly diverse background, ranging from bioorganic chemistry and molecular biology to clinical diagnostic research and development. He received a Ph.D. in bioorganic chemistry from the University of Southern California and a B.A. in chemistry from Concordia College. Simeonov then trained as a postdoctoral fellow at the Scripps Research Institute under Richard Lerner and Kim Janda. Prior to joining NIH in November 2004, Simeonov was a senior scientist at Caliper Life Sciences, a leading developer of microfluidic technologies, where he was responsible for basic research on novel assay methodologies and development of microfluidic products for research and clinical diagnostics.

Speakers
avatar for Anton Simeonov

Anton Simeonov

Scientific Director, National Institutes of Health
Anton Simeonov is the scientific director of the intramural Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH). The author or inventor on more than 145 peer-reviewed scientific publications and... Read More →



Thursday March 8, 2018 1:15pm - 2:00pm GMT
Music Hall 4

2:00pm GMT

Technology Forum - Is it Time for New Standards?
Join this interactive session to discuss the following question: “Do we need to define New Standards and how can SLAS support?

  • Do you think it is time for new standards?
  • Which standards exist?
  • What are your biggest pains and where would standards help?
  • Have you seen or experienced examples of good standardization in other industries? Please name a few...
  • Is there a need for stronger industrialization and therefore standards in Compound Management? Which would that be?
Panel includes:
  • Donat Elsener, Director of Sales and Marketing, Hamilton Storage
  • Ira Hoffman, President, HighRes Biosolutions
  • Tobi Winchester, Titian 
  • Clive Green, Astra Zeneca
  • Oliver Peter, Idorsia 



Speakers
avatar for Manuela Beil-Peter

Manuela Beil-Peter

Head of Liquid Handling & Automation, Analytik Jena AG


Thursday March 8, 2018 2:00pm - 3:00pm GMT
Music Hall 4

3:00pm GMT

3:45pm GMT

Session 2 - In control: the role of Quality in Compound Management
In control: the Value of Quality Control in Compound Management - session to highlight what, where and how Quality Control is applied in Compound Management processes and the benefits delivered to the Compound Management group and its customer.


Leveraging High Throughput Sample QC in Compound Management - Rosalia Gonzales
The capability to do rapid assessment of purity and identity is invaluable for compounds assessed in  lead optimization or hit identification programs as it helps build confidence in efficacy data obtained in in vitro screening in a timely manner.  Rapid communication of QC results delivered within the same timeframe as the screening results is ideal.  In HTS campaigns, a QC sample coming from the same well that made serial dilutions guarantees that the right hit is being confirmed.
Such capability can also be leveraged in ensuring the quality of the corporate compound collection.  Collection enhancement initiatives coupled with high throughput Sample QC capability ensures that "we get what we paid for".  Finally, having QC results in a centralized and accessible data system can enable "culling" of bad actors.
This talk will go through some best practices for setting up this capability and specific examples that highlight the use and impact of high throughput sample QC in early drug discovery.


Productivity increase in QC sample analysis, by implementation of processing automation - Jan Jacobsen
In a business where focus is on efficiency and cost consciousness, it is essential that decisions are taken, based on high quality data. In a research organization, QC data is one of the key tools to achieve this, by assessing the quality of the compounds, being evaluated.
With, an increase in number of samples needing QC, from a growing collection and limited resources, a solution to manage the task was needed.
We therefore decided back in 2014 to automate the time-consuming part of manually performed QC-data processing, by implementing Analytical studio from Virscidian
This presentation will highlight the increase in capacity generated by the implementation of Analytical studio. We will also present how, we have been able to increase the level of our QC strategy in an efficient way.
The talk will also explain the process, we have followed to both implement the software into our in-house processes and in close collaboration with the provider develop what we think is an advanced and state of the art analytical processing algorithm.

Enhance Quality & Lifespan of Samples by Utilizing Stability Analytics - Igor V. Tetko
 
Stability of chemical compounds is of utmost importance for the chemical industry.  The compounds, which have degraded can introduce significant artifacts in screening experiments and contribute both false positive and false negative errors. In the presentation, we will review the current state of the art to predict the stability of compounds. In particular, we will focus on the analysis of data provided by Specs, which includes stability data of more than ten thousands compounds, tested at several temperatures for up to 105 days. We will review different models developed using these data and will discuss the utility of using computational predictions to flag potentially unstable compounds.

The Value of Corporate Collections – Tracking Hits and Leads - Zoe Z. Zeliku

Constant improvement of systems is essential in drug development, requiring the feedback of past
successes and failures. However, when an acquired screening hit compound is modified, the
resultant lead compound is not always annotated with the original structure. As a result, when a
compound is declared as a lead, its original acquisition source might be unknown, thus preventing
acquisition strategies from being revised accordingly. GSK aim to develop a reliable system using
Chemical Space Networks (CSN's), to annotate declared leads with most likely hits by creating a
pathway that allows us to work backwards using several known examples. Once confident of
the progression pathway, identification of confirmed leads will enable us to work backwards to
identify the screening hits. Acquisition sources of hit compounds can then be found using internal
applications to create acquisition metrics as well as to advise on future acquisition strategies. The workflow tool Pipeline Pilot allows the design of protocols by connecting components which perform functions based on input data and defined parameters. This was used throughout to prove the suitability of using totally automated approach to complete the feedback loop simultaneously for many lead compounds, thus producing statistically valuable trends from past projects.

Speakers
avatar for Rose Gonzales

Rose Gonzales

Director, Pfizer
Rose Gonzales is Director of Compound Management & Distribution (CMD) at Pfizer Worldwide Research & Development, based in Groton, CT. She has been at Pfizer for 17 years, the last 7 in her current role overseeing the compound collection of Pfizer. Rose has undergraduate and graduate... Read More →
avatar for Jan Jacobsen

Jan Jacobsen

Compound Management Operations Lead, H.Lundbeck A/S
Jan was originally Trained as laboratory technician from School of Laboratory technicians in Copenhagen. He finalized his training at Haldor Topsoe, with synthesizing catalysts, pilot testing and participating in GC-FID method development.Jan has worked in few different companies... Read More →
avatar for Igor Tetko

Igor Tetko

Group Leader, Helmholtz Zentrum Muenchen (GmbH)
Dr. Tetko is Coordinator of Marie Skłodowska-Curie Innovative Training Network European Industrial Doctorate Horizon2020 project “Big Data in Chemistry” (http://bigchem.eu) and CEO of BIGCHEM GmbH, which offers innovative solutions for Big Data analysis.  His research interests covers (Q)SAR, QSPR, application and development of machine learning approaches to predict physico-chemical properties and biological activity of molecules, drug-design and... Read More →
avatar for Zoe Zeliku

Zoe Zeliku

Mrs, GlaxoSmithKline
Zoe Zeliku is a Scientific Leader in Discovery Supply at GSK where she manages a team looking after the acquisition and analysis of compounds entering the corporate compound collection. Zoe has over 25 years’ experience in Drug Discovery at GSK and her interests and specialty are... Read More →


Thursday March 8, 2018 3:45pm - 5:50pm GMT
Music Hall 4

5:50pm GMT

Vendor Snapshot Presentations - Quattro & Hamilton Storage
Speakers
avatar for Cathrin Pautsch

Cathrin Pautsch

Life Science Business Consultant, quattro research GmbH
IT solutions for Research & Developmentquattro research GmbH is an interdisciplinary team of scientists and IT specialists. We develop innovative solutions and products for our customers from the life science , pharma and chemistry industries.Modelling and optimization of scientific... Read More →
avatar for Hamilton Storage

Hamilton Storage

Sales Manager, Hamilton Storage
Hamilton Storage provides ultra-low temperature automated sample management solutions for the life science industries. Products include the Verso® for -20°C high-throughput tube and plate management, SAM HD and Hamilton BiOS® for -80°C biobanking, and the Askion C-line® systems... Read More →


Thursday March 8, 2018 5:50pm - 6:00pm GMT
Music Hall 4

7:00pm GMT

Networking Dinner
Join us for a fun evening of networking at the Rio Grande - walking distance from the conference venue!
Berlin beer tasting and German food sensations will help you connect with your peers!


Thursday March 8, 2018 7:00pm - 10:00pm GMT
Restaurant Rio Grande May-Ayim-Ufer 9 10997 Berlin
 
Friday, March 9
 

9:00am GMT

Session 3 -Working in partnership
 Working in Partnership - session focussed on working in collaborations (out-sourced partnerships, HTS, open innovation, industry-academia etc.)

Externalising GSK’s Archive Solid Compound Collection – partnering with Evotec and Titian - Darren Rimmer
GSK were faced with a decision to define a new strategy for the storage and supply of our Archive Solid compound collection. The factors contributing to defining a new strategy were the ageing and obsolescence of our Automated ‘Haystack’ bottle store, the associated vendor software that wasn’t going to be supported in the long term and replacing our bespoke Sample Inventory system. We looked at various options including a full replacement of a new automated store, relocating to a new building with manual stores or outsourcing. This is GSK’s story of how we partnered with Evotec and Titian to set up a new sample storage and supply system interfacing with Mosaic.

Using a Compound Management CRO to Join up your R&D Network - Sylviane Boucharens
Compound collections, no matter the size, are a valuable and fundamental asset of any R&D-based company, large or small. Therefore, compound management (aggregation, storage, picking, shipping in assay-ready format) is a key component of the Drug Discovery Process. Large and medium Pharma companies have often benefited from large capital investments to build a “State of the Art” compound repository store.  However, this approach is costly, and this critical activity is often under-valued and under-resourced by small pharma, biotechs, CROs and academia which prefer to focus their resource in their core expertise. For these groups, working in partnership with a compound management supplier may be an attractive option. By selecting the right partner, they can have access to advanced compound management infrastructure without costly capital investment and maintenance. In addition to this economic advantage, working in partnership with CRO experts in compound management may help to improve R&D processes, quality and timeliness within your own company.

Hit Discovery Constance (HDC) as a Drug Discovery Partnership Hub - Horst Flotow
Abstract: Built around an industrial compound management facility, HDC has been set up as a drug discovery partnership hub. The hub facilitates the translation of drug discovery ideas from assay concept through assay development all the way through screening and hit to lead through a network of partnerships and collaborations.

Designing a Compound Management platform with/for multiple partners to improve our level of service – H2L support at Evotec -Isabelle Bergère
The compound management group at Evotec Hamburg was created to support HTS campaigns but the need for hit/active to lead (H2L) support increased significantly over the last years. Evotec biologists used to manage the compounds for the hit/active to lead (H2L) programs by themselves but struggled with the growing demand and the rising level of complexity in the collaborations. The compound management team was asked to create a platform combining the advantage of the standardised and efficient processes already in place for HTS with flexibility to adjust to our partners’ needs.
We gathered the requirements of our partners and analysed the variability in the existing process.
Data management support has been key to setup the new process successfully. Several web tools have been developed in house to ensure data integrity from compound registration up to reporting.
Furthermore, formats used by the biologists needed to be categorised in order to define standard layouts.
The presentation will give you an insight on the new platform, which allowed us last year to support 25 projects with ca. 100 assays contributing to shorten the cycle time of projects.



Speakers
avatar for Isabelle Bergere

Isabelle Bergere

Group Leader Compound Management, Evotec AG
Isabelle Bergère studied chemistry at the University of Rouen in France and achieved a PhD in natural product chemistry at the Georg-August University in Göttingen, Germany. She started her industrial career in 2001 at AnalytiCon discovery in Potsdam, Germany as a structure elucidator... Read More →
avatar for Sylviane Boucharens

Sylviane Boucharens

Co-founder and COO, BioAscent Discovery Ltd.
Dr Sylviane Boucharens is Chief Operation and Scientific Officer and co-founder of BioAscent Discovery Ltd. a new venture offering services and expertise in Compound Management. She is also responsible of the Compound Management of the European Lead Factory.Sylviane started her career... Read More →
avatar for Horst Flotow

Horst Flotow

CEO, HDC GmbH
Talk to me about partnering your drug discovery projects to meeting your HTS and compound management needs
avatar for Darren Rimmer

Darren Rimmer

Solid Ops and Shipping Logistics Group Leader, GlaxoSmithKline
Darren joined SmithKlineBeecham in 1997 following graduation from the University of Hertfordshire, Hatfield. At that time the Compound Management group was really in its infancy and was part of the Screening group based in Harlow, Essex. With over 15 years’ experience in the world... Read More →


Friday March 9, 2018 9:00am - 11:10am GMT
Music Hall 4

11:10am GMT

Vendor Snapshot Presentation - Labcyte
Speakers
avatar for Labcyte

Labcyte

Sales & Support Manager, Labcyte INc.


Friday March 9, 2018 11:10am - 11:15am GMT
Music Hall 4

11:15am GMT

11:45am GMT

Interactive Session - Let's Confront our Nightmares!
Let’s confront our nightmares!
Nobody is an island. Compound management teams act as a link in the knowledge production chains of industrial and academic organizations. These chains become increasingly complex, as more internal and external partners are involved. This makes R&D more powerful, but it also creates new dependencies and vulnerabilities. At the same time, pressure mounts to be faster and more efficient.
Delays or failures in the production chain can be disruptive. Identifying and resolving their causes can be challenging and stressful.
How do you cope with complexity? Where do you see big risks, and how do you mitigate them? How will processes improve in the future? Let’s share our experiences!

Friday March 9, 2018 11:45am - 12:30pm GMT
Music Hall 4

12:30pm GMT

Networking Lunch and Exhibition
Friday March 9, 2018 12:30pm - 1:30pm GMT
Music Hall 1-2-3

1:30pm GMT

Session 4 - Innovations To Improve Compound Management
Innovations to Improve Compound Management - session dedicated to showcasing novel technology solutions in IT and hardware.

The chemical universe database: molecules, fragments and ring systems - Jean-Louis Reymond, University of Bern
Chemical space describes the ensemble of all molecules that are possible by assembling atoms through covalent bonds. This concept is particularly relevant in drug discovery, where new molecular entities are constantly needed to develop new drugs addressing unmet medical needs. In our research we design cheminformatics methods for enumerating, mapping and virtual screening the chemical space of small organic molecules applicable to very large numbers of compounds,such as the chemical universe database GDB-17 listing 166 billion possible molecules up to 17 atoms of C, N, O, S, and halogens, the fragment database FDB17,and the ring systems database GDB4c. We then implement these methods to choose, synthesize and test molecules in the laboratory. I will describe our ongoing research to refine and expand our databases and how we use them to guide drug discovery projects.

The Scale-up from a Laboratory to a Technical Process for the Removal of Solvent from Samples - Dr. Mark Drewes, Bayer AG

In the past, we have removed the solvent from the bottles using vacuum centrifuges. However, our current machinery was no longer state of the art and spare parts were becoming rare. So a project was launched to find new alternatives. We had two possibilities;
To buy new vacuum centrifuges and to stay within a known technology, or
To evaluate other methods for removing our solvent mixture from different container types.
After an evaluation period, we chose the latter route and decided to make a radical change. We have now invested in the Cyro-Condensation Technology together with the corresponding drying cabinets.
During this presentation, I will explain why and how we were able to transform a simple laboratory process into a technical one which conforms to German legislation. This technology has now been successfully implemented into our routine workflow within the Compound Management Group.


Orchestrating the Amazon effect - Annette Wheelock, Pfizer
Chemical libraries are the lifeblood of drug discovery and with increasing numbers of chemical matter needing to be screened across a dizzying array of assays at ever decreasing cycle times, the need for compound management groups to efficiently orchestrate the work in the lab to meet screening demands is very critical.
Liquid handling automation certainly helps, however in order to conduct the score of tasks needed for incoming requests – from matching the compounds requests to their assay requirements (volume, conc., format/container type), to efficiently utilizing available liquid handlers and more importantly optimally manage the overall capacity of the compound management operations to consistently complete all orders for each given day – then it needs to be partnered with the right workflow manager.
Many logistics (as well as manufacturing) companies such as FedEx, Amazon use planning and scheduling software to improve their fulfillment and distribution processes. Could this type of functionality be used in the compound management space? Pfizer’s Groton Compound Management & Distribution (CMD) Sample Logistics group partnered with Xavo to explore this possibility, using Xavo Lab Logistics (XLL) workflow manager and in December 2017, XLL was successfully deployed to production in CMD’s Sample Logistics lab. This is the first time across the industry that an automated-scheduling/planning application has been used in a compound management setting.
This presentation will cover the journey to deployment, the efficiencies gained and lessons learned.

Operation Sea World: the next generation of liquid handling and storage platforms within Compound Management of Janssen, Raf Benoy, Janssen
In 2016 Janssen has decided to upgrade the infrastructure of Compound Management to be ready for the future. The practical goal was driven by 3 keywords: quality, speed and efficiency. The central LIMS system should be the Mosaic software of Titian. We are now halfway our boat trip. What is already installed into our processes and how have the different global teams achieved this? Are these hardware and software platforms the best solutions for our needs? What can be improved if we sail away for a next project after 2018? This Overview will show you how Janssen has dived into the Technology World of Hardware and Software, when it looked for “State-of-the-art Fishes in the Big Ocean”.

Improved Sample Integrity with Acoustic Tubes utilising Acoustic Liquid Handling, Kevin Cross, AstraZeneca
To revolutionize AstraZeneca’s sample management capability with acoustic based technology, we have begun the transition to acoustically qualified storage tubes. A key design requirement in our decision to adopt a new acoustic sample storage vessel was assurances that the design would maintain high standards of sample integrity to support 10-years of screening. In this talk, AstraZeneca will discuss the aspects of the acoustic tube’s design leading to improved sample integrity as well as detailing the exacting requirements set for these experiments. Finally, results from the extensive sample integrity testing performed will be shown, proving the efficacy of the new acoustic storage tube.

Speakers
avatar for Raf Benoy

Raf Benoy

Scientist, Janssen
avatar for Kevin Cross

Kevin Cross

Senior Scientist - Automation Specialist, AstraZeneca
An innovative scientist with specialist knowledge of acoustic dispensing, Kevin’s experience extends to collaborative working both internally and externally; developing creative ideas, concepts and solving technical problems. As technical lead on AstraZeneca’s collaborative acoustic... Read More →
avatar for Mark Drewes

Mark Drewes

Ph.D., Bayer AG
Mark Drewes received his undergraduate and master of science in chemistry from the University of Natal, Pietermaritzburg, South Africa. He completed his Ph.D. and postdoctoral research at the Philipps University of Marburg, Germany. His industrial career started as an organic chemist... Read More →
avatar for Jean-Louis Reymond

Jean-Louis Reymond

Professor, University of Bern
Jean-Louis Reymond is professor of chemistry and chemical biology at the University of Bern, Switzerland. He studied chemistry and biochemistry at the ETH Zürich and obtained his Ph.D. in 1989 at the University of Lausanne on natural products synthesis. After a post-doc and assistant... Read More →
avatar for ANNETTE WHEELOCK

ANNETTE WHEELOCK

SR. SCIENTIST, PFIZER - Groton
Annette Wheelock is a Senior Scientist in the Compound Management & Distribution (CMD) group at Pfizer Worldwide Research & Development, based in Groton, CT.  She has an undergraduate degree in chemistry and has been with Pfizer for 21 years, the last year joining the Sample Logistics... Read More →


Friday March 9, 2018 1:30pm - 3:40pm GMT
Music Hall 4

3:40pm GMT

Vendor Snapshot Presentation - TTP Labtech
Speakers
avatar for TTP Labtech

TTP Labtech

TTP Labtech
TTP Labtech develops and manufactures robust automated solutions for automated sample storage and low volume liquid handling. Biobanking solutions from ambient to -80oC for 2D barcoded tubes offer truly scalable solutions for libraries from 50,000 to 500,000+ samples with unique modular... Read More →


Friday March 9, 2018 3:40pm - 3:45pm GMT
Music Hall 4

3:45pm GMT

Closing
Friday March 9, 2018 3:45pm - 4:00pm GMT
Music Hall 4